Nivolumab + Ipilimumab Therapy as Frontline Therapy for Advanced Renal Cell Carcinoma

EP: 1.Patient Profile Presentation: A 61-Year-Old Man with Advanced Renal Cell Carcinoma

EP: 2.Considerations for Treatment Decision Making for Advanced Renal Cell Carcinoma

EP: 3.Lenvatinib + Pembrolizumab as Frontline Therapy for Advanced Renal Cell Carcinoma

EP: 4.Adverse Events with IO-TKI Combination Treatment Regimens

EP: 5.Impact of Adjuvant Pembrolizumab Approval on RCC Treatment Landscape

EP: 6.Patient Profile Presentation: A 41-Year-Old Male with Advanced Renal Cell Carcinoma

Now Viewing

EP: 7.Nivolumab + Ipilimumab Therapy as Frontline Therapy for Advanced Renal Cell Carcinoma

EP: 8.Advanced Renal Cell Carcinoma and Brain Metastases

EP: 9.Toxicities and Quality of Life with IO-IO Therapies in Patients with Advanced RCC

EP: 10.Role of Community and Academic Centers in the Treatment of Patients with Advanced RCC

EP: 11.Advanced Renal Cell Carcinoma: Clinical Practice Pearls

EP: 12.Patient Profile Presentation: A 58-Year-Old Woman Presenting with Gross Hematuria

EP: 13.First-Line IO-TKI Combination Treatment Regimens for Advanced RCC

EP: 14.Selecting RCC Patients with Lenvatinib + Pembrolizumab Therapy and Appropriate Dosing Strategies

EP: 15.Adverse Events with IO-TKI Combination Regimens for Advanced RCC and Their Management

EP: 16.Duration of Treatment with IO-TKI Regimens and Treatment Options at Progression

EP: 17.Patient Profile Presentation: A 48-Year-Old Man Presenting with a Right Renal Mass

EP: 18.Approved First-Line IO-IO Combination Treatment Regimens for Advanced RCC

EP: 19.Adverse Events in IO-IO Combination Treatment Regimens for Advanced RCC

EP: 20.Patient Profile Presentation: A 72-Year-Old Man Presenting with Hematuria

EP: 21.Using Cabozantinib + Nivolumab to Treat Advanced Renal Cell Carcinoma

EP: 22.The Future of Advanced Renal Cell Carcinoma Management

EP: 23.Patient Profile Presentation: A 56-Year-Old Man with Metastatic Clear Cell RCC

EP: 24.Front-Line Lenvatinib + Pembrolizumab Combination Regimens for Advanced RCC: Selecting Patients and Dose

EP: 25.Toxicities with IO-TKI Combination Regimens for Advanced RCC and Their Management

EP: 26.Sequencing Therapies for Advanced RCC

EP: 27.Patient Profile Presentation: A 70-Year-Old Man with Stage 4 Clear Cell RCC

EP: 28.Nivolumab + Ipilimumab Combination Regimen for Advanced RCC

EP: 29.Advanced RCC Patient Referrals from Community Oncologists

EP: 30.Patient Profile Presentation: A 56-Year-Old Man with Clear Cell RCC

EP: 31.Cabozantinib + Nivolumab Regimen in the Treatment of Advanced RCC

EP: 32.Unmet Needs in the Management of Advanced RCC

Eric Jonasch, MD: Dr Bhatia, please describe your decision-making process in choosing ipilimumab-nivolumab for this patient. I know this was back when the other regimens weren’t approved, but if you could do it again, would you still see this patient as a very good candidate for ipilimumab-nivolumab? What would your differentiating factors be between I/O [immuno-oncology] and I/O–TKI [tyrosine kinase inhibitor]?

Sumeet Bhatia, MD: If this patient came in today, I probably wouldn’t have used nivolumab-ipilimumab. Most of these patients would have been treated with a TKI- and I/O–based regimen, so this has to do with the availability at that time, and nivolumab-ipilimumab does have far more toxicity compared with these other regimens. The factor that led me to never use nivolumab-ipilimumab up front is patients with hematuria. Though as you described in the previous case, you’ve done better with it. If somebody has brain metastases, that’s another reason why I will start with nivolumab-ipilimumab up front. But otherwise, in my practice, I’ve more or less moved to an I/O–TKI–based regimen. One thing that bothers me: what do we use after that when people relapse? Management of hypertension and the presence of comorbidities definitely guide our decision-making and how we choose what therapies for which patients.

Eric Jonasch, MD: Great. Thank you.

Transcript edited for clarity.